Effect of gastric banding on aminoterminal pro-brain natriuretic peptide in the morbidly obese

Obesity Research

Volumn 11, Issue 6, 2003, Pages 695-698

  Hanusch Enserer, Ursula ^a   Hermann, Katharina Maria ^b   Cauza, Edmund ^a   Spak, Marita ^a   Mähr, Bruno ^d   Dunky, Attila ^a   Rosen, Harald R ^c   Köller, Ursula ^b   Prager, Rudolf ^b  

^a WILHELMINEN HOSPITAL   (Austria)

^b GENERAL HOSPITAL LINZ   (Austria)

^c Wiener Krankenanstaltenverbund   (Austria)

^d KAISER FRANZ JOSEF HOSPITAL   (Austria)

Author keywords

Aminoterminal pro brain natriuretic peptide (NT proBNP); Hypertension; Laparoscopic adjustable gastric banding (LAGB); Left ventricular hypertrophy; Morbid obesity

Indexed keywords

EID: 9144220473     PISSN: 10717323     EISSN: None     Source Type: Journal    
DOI: 10.1038/oby.2003.99     Document Type: Article

References (15)

1. Lauer MS, Anderson KM, Kannel WB, Levy D. The impact of obesity on left ventricular mass and geometry. JAMA. 1991;266:231-6.
2. Yamamoto K, Burnett JC, Jougaski M, et al. Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy. Hypertension. 1996;28:988-94.
3. Committee to Develop Criteria for Evaluating the Outcomes of Approaches to Prevent and Treat Obesity. Weighing the options: criteria for evaluating weight-management programs. Obes Res 1995;3:591-604.
4. Sjöström CD, Peltonen M, Sjöström L. Blood pressure and pulse pressure during long-term weight loss in the obese: the Swedish Obese Subjects (SOS) Intervention Study. Obes Res. 2001;9:188-95.
5. Gastrointestinal surgery for severe obesity. National Institutes of Health Consensus Development Conference Statement. Am J Clin Nutr 1992;55(Suppl2):S615-9.
6. Luchner A, Burnett JC Jr, Jougasaki M, et al. Evaluation of brain natriuretic peptide as marker of left ventricular dysfunction and hypertrophy in the population. J Hypertens. 2000;18:1121-8.
7. Qi W, Mathisen P, Kjekhus J, et al. Natriuretic peptides in patients with aortic stenosis. Am Heart J. 2001;142:725-32.
8. Packer M, Cohn JN. Consensus recommendations for the management of chronic heart failure. Am J Cardiol. 1999;83:1A-32A.
9. Karason K, Wallentin I, Larsson Bo, Sjöström L. Effects of obesity and weight loss on left ventricular mass and relative wall thickness: survey and intervention study, BMJ. 1997;315:912-16.
10. Kanoupakis E, Michaloudis D, Fraidakis O, Parthenakis F, Vardas P, Melissas J. Left ventricular function and cardiopulmonary performance following surgical treatment of morbid obesity. Obes Surg. 2001;11:552-8.
11. Mc Murray RW Jr, Vesely DL. Calorie-restricted weight reduction, blood pressure, and atrial natriuretic peptides. Nutrition 1993;9;178-82.
12. Messaoudi L, Donckier J, Stoffel M, Ketelsberger JM, Kolanowski J. Changes in blood pressure and in vasoactive and volume regulatory hormones during semistarvation in obese subjects. Metabolism. 1998;47:592-7.
13. Minami J, Nishikimi T, Ishimitsu T, et al. Effect of a hypocaloric diet on adrenomedullin and natriuretic peptides in obese patients with essential hypertension. J Cardiovasc Pharmacol. 2000;36:S83-6.
14. McCullough PA, Nowak RM, McCord J, et al. B-type natriuretic peptide and clinical judgement in emergency diagnosis of heart failure: analysis from Breathing Not Properly (BNP) Multinational Study. Circulation. 2002;106:416-22.
15. SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fraction. N Engl J Med. 1997;327:685-91.